Alector, Inc. (27)

Browse by Contract Category

Contracts

Retention Letter Agreement, dated March 23, 2021, among Mr. Calvin Yu and Alector, Inc (Filed With SEC on March 26, 2021)
Description of securities of the Registrant (Filed With SEC on February 25, 2021)
Equity Distribution Agreement, dated May 13, 2020, by and among Alector, Inc., Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC (Filed With SEC on May 13, 2020)
2019 Collaboration Agreement between the Registrant and Adimab, LLC, dated August 16, 2019 (Filed With SEC on November 12, 2019)
Lease between the Registrant and HCP Oyster Point III, LLC, dated June 27, 2018 (Filed With SEC on January 7, 2019)
Outside Director Compensation Policy (Filed With SEC on March 24, 2020)
Description of securities of the Registrant (Filed With SEC on March 24, 2020)
Underwriting Agreement, dated as of January 29, 2020, among the Registrant, Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC,... (Filed With SEC on February 4, 2020)
Form of Underwriting Agreement, including Form of Lock-up Agreement (Filed With SEC on January 27, 2020)
Confirmatory Offer Letter between the Registrant and Robert Paul, M.D., Ph.D (Filed With SEC on January 29, 2019)
Confirmatory Offer Letter between the Registrant and Arnon Rosenthal, Ph.D (Filed With SEC on January 29, 2019)
Confirmatory Offer Letter between the Registrant and Robert King, Ph.D (Filed With SEC on January 29, 2019)
Confirmatory Offer Letter between the Registrant and Sabah Oney, Ph.D (Filed With SEC on January 29, 2019)
Confirmatory Offer Letter between the Registrant and Calvin Yu (Filed With SEC on January 29, 2019)
2019 Equity Incentive Plan and forms of agreements thereunder, to be in effect upon the completion of this offering (Filed With SEC on January 7, 2019)
Form of Underwriting Agreement, including Form of Lock-up Agreement (Filed With SEC on January 7, 2019)
Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology, Ltd., dated October 16, 2017 (Filed With SEC on January 7, 2019)
Sublease between the Registrant and CytomX Therapeutics, Inc., dated April 25, 2016 (Filed With SEC on January 7, 2019)
Amended and Restated Registration Rights Agreement among the Registrant and certain of its stockholders, dated April 26, 2018 (Filed With SEC on January 7, 2019)
2019 Employee Stock Purchase Plan, to be in effect upon the completion of this offering (Filed With SEC on January 7, 2019)
Specimen common stock certificate of the Registrant (Filed With SEC on January 7, 2019)
Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on January 7, 2019)
Third Amended and Restated Collaboration Agreement between the Registrant and Adimab, dated September 19, 2016, as amended (Filed With SEC on January 7, 2019)
Form of Change in Control and Severance Agreement between the Registrant and certain of its executive officers (Filed With SEC on January 7, 2019)
2017 Stock Option and Grant Plan, as amended, and forms of agreement thereunder (Filed With SEC on January 7, 2019)
Executive Incentive Compensation Plan (Filed With SEC on January 7, 2019)
Outside Director Compensation Policy (Filed With SEC on January 7, 2019)